PR Newswire
LOS ANGELES, May 23, 2016
LOS ANGELES, May 23, 2016 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief
Executive Officer of ImmunoCellular, will present a corporate overview and business update at the Marcum MicroCap Conference on
Thursday, June 2, 2016 at 2:00 pm ET at the Grand Hyatt hotel,
New York, New York.
To access the live audio webcast of the Marcum presentation, please log on through a link located in the Investors section of
ImmunoCellular's website at www.imuc.com, under the Events
& Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is
developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product
candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on
glioblastoma stem cells, is open for patient screening. ImmunoCellular's pipeline also includes: ICT-121, a patient-specific,
dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a
patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell
research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. To
learn more about ImmunoCellular, please visit www.imuc.com.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green
Investor Relations
415.348.0010
jane@jmgcomm.com
Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-present-at-marcum-microcap-conference-on-june-2-2016-300272496.html
SOURCE ImmunoCellular Therapeutics, Ltd.